NDAORALTABLETPriority Review
Approved
Aug 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKEEGA is a fixed-dose combination of niraparib (a PARP inhibitor) and abiraterone acetate (an androgen synthesis inhibitor) approved in August 2023 as an oral tablet for metastatic castration-resistant prostate cancer (mCRPC). This combination targets DNA repair deficiency and androgen signaling pathways simultaneously in men with prostate cancer.
$0.567MPart D
Peak16.9 years to LOEEarly commercial phase post-launch with modest initial Medicare utilization; brand teams should expect ramp-building activities over the next 2-3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Prostate NeoplasmsGenital Neoplasms, MaleUrogenital Neoplasms+1 more
Career Relevance
Working on AKEEGA offers career opportunity in a high-value specialty oncology segment (prostate cancer) with a newly approved, differentiated mechanism and a long patent runway. The product is in peak commercial phase post-launch, signaling growing team buildout and market development activities that will expand roles in field sales, account management, and medical affairs over the next 3-5 years.
Brand Manager
Worked on AKEEGA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.